Corcept Therapeutics (CORT) Gross Margin (2016 - 2025)
Historic Gross Margin for Corcept Therapeutics (CORT) over the last 10 years, with Q3 2025 value amounting to 97.79%.
- Corcept Therapeutics' Gross Margin fell 6400.0% to 97.79% in Q3 2025 from the same period last year, while for Sep 2025 it was 98.19%, marking a year-over-year decrease of 2500.0%. This contributed to the annual value of 98.39% for FY2024, which is 2700.0% down from last year.
- Per Corcept Therapeutics' latest filing, its Gross Margin stood at 97.79% for Q3 2025, which was down 6400.0% from 98.23% recorded in Q2 2025.
- Corcept Therapeutics' 5-year Gross Margin high stood at 98.73% for Q2 2022, and its period low was 97.79% during Q3 2025.
- Its 5-year average for Gross Margin is 98.5%, with a median of 98.56% in 2022.
- As far as peak fluctuations go, Corcept Therapeutics' Gross Margin skyrocketed by 4200bps in 2021, and later tumbled by -6400bps in 2025.
- Quarter analysis of 5 years shows Corcept Therapeutics' Gross Margin stood at 98.63% in 2021, then fell by 0bps to 98.56% in 2022, then increased by 0bps to 98.61% in 2023, then dropped by 0bps to 98.37% in 2024, then decreased by -1bps to 97.79% in 2025.
- Its Gross Margin stands at 97.79% for Q3 2025, versus 98.23% for Q2 2025 and 98.47% for Q1 2025.